Ashutosh Sharma
Corporate Officer/Principal bei New Jersey Institute of Technology
Profil
Ashutosh Sharma is Vice President of Product and Process Development for Vyteris Holdings, Inc. Previously, he was Program Manager of Becton Dickinson.
Dr. Sharma received an MD from Rensselaer Polytechnic Institute and a Bachelor's degree from the Indian Institute of Technology in Kanpur, India.
Aktive Positionen von Ashutosh Sharma
| Unternehmen | Position | Beginn |
|---|---|---|
| New Jersey Institute of Technology | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Ashutosh Sharma
| Unternehmen | Position | Ende |
|---|---|---|
| BECTON, DICKINSON AND COMPANY | Corporate Officer/Principal | - |
Vyteris, Inc.
 Vyteris, Inc. Pharmaceuticals: MajorHealth Technology Vyteris, Inc. develops, manufactures and commercializes pharmaceutical products. It is engaged in the process of developing first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration. The drug delivery patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. The company was founded on July 19, 2000 and is headquartered in Fair Lawn, NJ. | Corporate Officer/Principal | - |
Ausbildung von Ashutosh Sharma
| Rensselaer Polytechnic Institute | Doctorate Degree |
| Indian Institute of Technology Kharagpur | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BECTON, DICKINSON AND COMPANY | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Vyteris, Inc.
Vyteris, Inc. Pharmaceuticals: MajorHealth Technology Vyteris, Inc. develops, manufactures and commercializes pharmaceutical products. It is engaged in the process of developing first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration. The drug delivery patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. The company was founded on July 19, 2000 and is headquartered in Fair Lawn, NJ. | Health Technology |
